BP11129 PLGA 65:35, Carboxyl-Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa

PLGA 65:35, Carboxyl-Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa Description

PLGA 65:35, Carboxyl-Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa is a biodegradable copolymer composed of lactic acid and glycolic acid in a 65:35 ratio. The carboxyl termination modifies the chain end to promote hydrolytic degradation and facilitate controlled drug release. The intrinsic viscosity and low molecular weight enable formulation adjustments tailored for specific in vivo resorption rates, making it suitable for drug delivery and tissue engineering scaffold applications.

PLGA 65:35, Carboxyl-Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa Applications

1.         Healthcare
- Used as a matrix in biodegradable drug delivery systems to achieve controlled release by utilising carboxyl termination for predictable hydrolysis.
- Applied in tissue engineering scaffolds to support cell proliferation and gradual material resorption via modulated degradation kinetics.

2.         Industrial
- Serves as an encapsulation material in transient electronics to attain temporary functionality and simplified recycling by enabling controlled degradation.

PLGA 65:35, Carboxyl-Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa Packing

The polymer is packaged in moisture-resistant, inert containers to mitigate contamination and preserve material integrity. Sealed pouches are placed within rigid, protective boxes to prevent physical and environmental damage. Storage recommendations include cool, dry, and static-free conditions. Custom packaging options are available to accommodate specific handling requirements during transport and long-term storage.

Additional Information

Biodegradable polymers such as PLGA play a critical role in modern biomedical applications. Their degradation profile is predominantly determined by their chemical composition and molecular structure, which can be adjusted to meet specific therapeutic or tissue engineering demands. Detailed characterisation methods, including DSC and FT-IR, are routinely used to establish polymer behaviour under physiological conditions.

Advancements in polymer synthesis have led to a better understanding of controlled degradation kinetics. Through systematic variation of monomer ratios and end-group modifications, researchers fine-tune these materials to optimise performance in applications ranging from pharmaceutical delivery to temporary medical implants. This continuous innovation supports the development of materials that can safely degrade within the body over a predetermined timeframe.

Regulatory Note: This material is intended for industrial and research applications. It is the customer's responsibility to ensure compliance with all relevant safety and regulatory standards in their intended use.